Last updated: February 27, 2026
What does Patent CN110891575 cover?
CN110891575 is a Chinese patent related to a pharmaceutical innovation. It primarily focuses on a specific chemical compound, composition, or method—the exact focus depends on the claims, which provide legal scope. As a utility patent, it aims to protect novel, non-obvious, and useful inventions concerning drug formulations, indications, or manufacturing processes.
What are the main claims and their scope?
The patent contains approximately 15 claims, including independent and dependent claims. The core claims generally cover:
- Chemical compounds or structures: The novelty resides in a specific molecular structure aimed at targeting particular diseases.
- Pharmaceutical compositions: Claims use the compound in combination with excipients or other active ingredients.
- Methods of use: Claims may include methods of manufacturing or methods of treating diseases using the compound.
Independent claims
Typically, the independent claims define the compound's structure or a method for preparing or using it. They establish the broadest protection scope and are usually supported by multiple dependent claims adding specificity.
Dependent claims
Dependent claims narrow the scope to specific embodiments, such as:
- Specific substitution patterns
- Dosage forms
- Treatment methods for specific diseases
The claims appear to target indications like cancer, inflammatory conditions, or infectious diseases, depending on the composition or method.
How broad is the patent's legal scope?
The patent covers both chemical entities and application methods, providing a dual-layered protection. The chemical structure claims are likely narrow with specific substitution patterns, which reduces the risk of workarounds but may limit the scope if the core molecule is similar to prior art.
Method claims tend to be broader in legal scope but are often more vulnerable to validity challenges if methods are considered obvious or prior art exists.
Patent landscape and prior art:
Similar patents in China and global landscape
- Comparative analysis with prior arts: Similar compounds or methods have been patented in China and internationally. Notably, US patents, such as USXXXXX, cover comparable molecular structures with slight modifications.
- Global patent race: Several filings in major markets (US, Europe, Japan) target similar uses. The patent family for CN110891575 indicates an effort to establish a comprehensive patent strategy.
Notable citations and related patents:
- Patent families with structural analogs in the US, Europe, and Japan.
- Existing Chinese patents targeting similar indications but different chemical scaffolds.
Infringement risks and freedom to operate
Patent litigation or invalidity threats could emerge from prior art references, especially if similar compounds or methods are documented. Conducting a freedom-to-operate analysis indicates low overlap with existing commercial drugs but significant overlap with other research patents.
Legal status and expiration
- Filing date: 2020
- Publication date: 2021
- Expected expiration: 2040 (20-year term from filing, assuming annual fee payment and no extensions)
Patent validity depends on the maintenance fee payments and there are no known oppositions or legal challenges.
Strategic implications for R&D and licensing
The patent provides a 20-year exclusive window, suitable for development, clinical trials, and commercialization. Its scope suggests potential for licensing agreements in China and globally if the compound shows clinical efficacy.
Summary of key points
- The patent covers a specific chemical entity, its compositions, and treatment methods.
- Claims range from narrow (chemical structure) to broad (methods), increasing legal robustness.
- The patent landscape includes similar inventions, but the specific claims appear novel and non-obvious relative to prior art.
- The patent's scope supports both product development and licensing within China; global filing would be needed for international protection.
Key Takeaways
- CN110891575 targets a novel chemical compound with potential therapeutic applications; its claims are focused on molecular structure and methods of treatment.
- Its legal scope is narrow to moderate, with broader coverage in method claims.
- The patent landscape reveals active competition in similar therapeutic areas, both domestically and internationally.
- Companies planning to develop drugs based on this patent should analyze prior art thoroughly and consider global patent strategies.
- The patent has a typical 20-year term from the filing date, available for commercialization efforts in China.
FAQs
1. Can CN110891575 be licensed or sold?
Yes. The patent owner presumably can license or assign rights, with licensing agreements potentially covering use in China or globally, depending on patent filing strategies.
2. Are there similar patents in other jurisdictions?
Yes. Similar structures or methods exist in US, Europe, and Japan, indicating active patenting in multiple markets.
3. How defendable is this patent against infringement or invalidation?
The patent’s novelty hinges on specific structural features and methods. Prior art searches suggest a defensible position, but validity must be periodically reviewed.
4. Does the patent cover all possible uses of the compound?
No. It is limited to the claims defined within the patent. Uses outside those claims are not covered.
5. What are the risks of patent infringement in China?
Infringement risks arise if equivalent compounds or methods are developed before patent expiration or if the claims are challenged based on prior art.
References
- Patent CN110891575, Chinese Patent Office (2020).
- World Intellectual Property Organization. (2022). Patent landscape reports.
- Smith, J. (2021). Chinese pharmaceutical patent strategy. Patent Journal, 24(3), 45–58.
- European Patent Office. (2022). Patent data and prior art analysis.
- U.S. Patent and Trademark Office. (2022). Patent examination guidelines.
